Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial): an open-label, multicentre, randomised, controlled trial

I van Moort, T Preijers, LH Bukkems… - The Lancet …, 2021 - thelancet.com
Background Dosing of replacement therapy with factor VIII concentrate in patients with
haemophilia A in the perioperative setting is challenging. Underdosing and overdosing of …
被引用次数：14 相关文章

[引用][C] Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial): an open-label, multicentre, randomised, controlled trial

I Moort, T Preijers, LH Bukkems, H Hazendonk… - 2021 - repository.ubn.ru.nl
BACKGROUND: Dosing of replacement therapy with factor VIII concentrate in patients with
haemophilia A in the perioperative setting is challenging. Underdosing and overdosing of …

Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial): an open-label, multicentre, randomised, controlled trial.

I van Moort, T Preijers, LH Bukkems… - The Lancet …, 2021 - europepmc.org
Background Dosing of replacement therapy with factor VIII concentrate in patients with
haemophilia A in the perioperative setting is challenging. Underdosing and overdosing of …

Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial): an open-label, multicentre, randomised, controlled trial

OPTI-CLOT study group - Lancet …, 2021 - researchinformation.amsterdamumc …
Background: Dosing of replacement therapy with factor VIII concentrate in patients with
haemophilia A in the perioperative setting is challenging. Underdosing and overdosing of …

Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial): an open-label, multicentre, randomised, controlled trial

I van Moort, T Preijers, LH Bukkems… - The Lancet …, 2021 - Elsevier
Background Dosing of replacement therapy with factor VIII concentrate in patients with
haemophilia A in the perioperative setting is challenging. Underdosing and overdosing of …

Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial): an open-label, multicentre, randomised, controlled trial

I van Moort, T Preijers, LH Bukkems… - Lancet …, 2021 - research.rug.nl
Background Dosing of replacement therapy with factor VIII concentrate in patients with
haemophilia A in the perioperative setting is challenging. Underdosing and overdosing of …

Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial): an open-label, multicentre, randomised, controlled trial

I Moort, T Preijers, LH Bukkems… - The Lancet …, 2021 - scholarlypublications …
Background Dosing of replacement therapy with factor VIII concentrate in patients with
haemophilia A in the perioperative setting is challenging. Underdosing and overdosing of …

Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial): an open-label, multicentre, randomised, controlled trial

I van Moort, T Preijers, LH Bukkems… - 2021 - pubmed.ncbi.nlm.nih.gov
Background Dosing of replacement therapy with factor VIII concentrate in patients with
haemophilia A in the perioperative setting is challenging. Underdosing and overdosing of …

Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial): an open-label, multicentre, randomised, controlled trial

I van Moort, T Preijers, LH Bukkems… - The Lancet …, 2021 - cris.maastrichtuniversity.nl
Background Dosing of replacement therapy with factor VIII concentrate in patients with
haemophilia A in the perioperative setting is challenging. Underdosing and overdosing of …